Antineoplastics
1
Reactions 1369 - 17 Sep 2011 Antineoplastics Various toxicities: case report A man developed various toxicities during his first, second and third lines of chemotherapy [outcomes not stated]. On 20 November 2003, the man commenced first line chemotherapy with S-1 120 mg/day for 3 weeks, followed by 2 weeks’ rest, with cisplatin 60 mg/m 2 on day 8 [routes not stated]. He received three courses, but developed grade 2 anaemia during treatment [time to reaction onset not stated]. On 29 March 2004, second line chemotherapy was started for metastatic disease with paclitaxel 60 mg/m 2 via systemic dosing and 20 mg/m 2 via interperitoneal dosing for 2 weeks, followed by 1 week of rest [frequency not clearly stated]. On 10 June, oral S-1 100 mg/day (2 weeks on–1 week off) was added; he received 16 courses. During second line chemotherapy, he developed grade 2 anaemia, grade 1 alopecia and grade 1 leucopenia [times to reactions onset not stated]. Third line chemotherapy was started on 2 June 2005 with the addition of tri-weekly irinotecan 50 mg/m 2 [route not stated] to his existing paclitaxel and S-1 regimen. He received 20 courses of third line chemotherapy. In July 2005, he developed grade 2 anaemia and grade 1 liver function impairment. Interperitoneal paclitaxel dosing was stopped. He died on 4 November 2005. Seshimo K, et al. A case of gastric cancer with peritoneal dissemination who achieved long survival by successive treatments with S-1 in combination with CDDP, paclitaxel and irinotecan. Gan to Kagaku Ryoho 36: 1741-1744, No. 10, Oct 2009 [Japanese; summarised from a translation] - Japan 803060352 1 Reactions 17 Sep 2011 No. 1369 0114-9954/10/1369-0001/$14.95 © 2010 Adis Data Information BV. All rights reserved
Transcript of Antineoplastics
Reactions 1369 - 17 Sep 2011
Antineoplastics
Various toxicities: case reportA man developed various toxicities during his first,
second and third lines of chemotherapy [outcomes notstated].
On 20 November 2003, the man commenced first linechemotherapy with S-1 120 mg/day for 3 weeks, followedby 2 weeks’ rest, with cisplatin 60 mg/m2 on day 8 [routesnot stated]. He received three courses, but developedgrade 2 anaemia during treatment [time to reaction onsetnot stated].
On 29 March 2004, second line chemotherapy wasstarted for metastatic disease with paclitaxel 60 mg/m2 viasystemic dosing and 20 mg/m2 via interperitoneal dosingfor 2 weeks, followed by 1 week of rest [frequency notclearly stated]. On 10 June, oral S-1 100 mg/day (2 weekson–1 week off) was added; he received 16 courses. Duringsecond line chemotherapy, he developed grade 2 anaemia,grade 1 alopecia and grade 1 leucopenia [times to reactionsonset not stated].
Third line chemotherapy was started on 2 June 2005 withthe addition of tri-weekly irinotecan 50 mg/m2 [route notstated] to his existing paclitaxel and S-1 regimen. Hereceived 20 courses of third line chemotherapy. In July2005, he developed grade 2 anaemia and grade 1 liverfunction impairment. Interperitoneal paclitaxel dosing wasstopped. He died on 4 November 2005.Seshimo K, et al. A case of gastric cancer with peritoneal dissemination whoachieved long survival by successive treatments with S-1 in combination withCDDP, paclitaxel and irinotecan. Gan to Kagaku Ryoho 36: 1741-1744, No. 10,Oct 2009 [Japanese; summarised from a translation] - Japan 803060352
1
Reactions 17 Sep 2011 No. 13690114-9954/10/1369-0001/$14.95 © 2010 Adis Data Information BV. All rights reserved
